Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single cell transcriptome profiling of kidney cell populations and the effect of liraglutide in diabetes

ABSTRACT: Single cell transcriptome profiling of kidney cell populations and the effect of liraglutide in diabetes

PROVIDER: PRJNA908106 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22516170_1.fastq.gz	Fastqsanger.gz
	SRR22516170_2.fastq.gz	Fastqsanger.gz
	SRR22516171_1.fastq.gz	Fastqsanger.gz
	SRR22516171_2.fastq.gz	Fastqsanger.gz
	SRR22516172_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 34

Similar Datasets

Single cell transcriptome profiling of kidney cell populations and the effect of liraglutide in diabetes

Project description:While incretin-based therapies are known to improve glucose control in diabetes, growing evidence suggests a glucose-independent mechanism in protection against kidney disease. To further investigate incretin effects in kidney, we examined long-term therapy with liraglutide, a Glucagon-like peptide 1 receptor (GLP1R) agonist, in diabetic (Ins2Akita) and control mice and profiled renal cell transcriptomes using single-cell sequencing.

2024-05-02 | GSE220045 | GEO

Liraglutide effect on STZ Mouse Kidney with diabetic nephropathy

Project description:The effect of liraglutide on the kidney proteome in the STZ mouse model compared to healthy and STZ diabetic control groups.

2019-01-18 | PXD003007 | Pride

dbdbLiraglutide - Effects of insulin and the glucagon-like peptide 1 receptor agonist liraglutide on the kidney proteome in db/db mice

Project description:db/db mouse kidney given liraglutide or insulin compared to db/db vehicle and healthy vehicle, 12 weeks dosing, all included db/db mice over 16 mM blood glucose level.

2017-03-29 | PXD002988 | Pride

RNA-Seq analysis on the liver of mice treated with high-fat diet and liraglutide

Project description:GLP-1 based diabetes drugs are effective to reduce hepatic lipid accumulation beyong glycemic control. As GLP-1 receptor (GLP-1R) is not expressed in hepatocytes, the mechanism behind the beneficial effects of GLP-1 based drugs on the liver remained elusive. Several studies have shown that the expression of hepatic fibroblast growth factor 21 (FGF21) can be stimulated by GLP-1-based drugs. Therefore, the present study aimed to assess such stimulation in mice and in mouse primary hepatocytes, determine whether hepatic FGF21 mediates functions of the GLP-1R agonist liraglutide, and to explore the potential mechanisms of liraglutide regulating the expression of FGF21. In high-fat diet induced obese mice, we observed hepatic and plasma FGF21 elevation, improved glucose disposal, and reduced plasma triglyceride levels by liraglutide treatment. Moreover, RNA-sequencing on the liver suggested that Fgf21 was the most upregulated gene after liraglutide treatment. In liver-specific FGF21 knock-out mice on high-fat and high-fructose diet, the body-weight gain attenuation and lipid homeostatic effects of liraglutide was lost or significantly reduced. These studies implied that hepatic FGF21 was the critical mediator of liraglutide-induced metabolic improvement.

2021-03-16 | GSE168937 | GEO

Identifying the molecular mechanisms that underlie impaired kidney development due to maternal diabetes.

Project description:The prevalence of diabetes has significantly increased among women of childbearing age worldwide, and it is known that infants who are exposed to maternal diabetes in utero are at increased risk of congenital anomalies of the kidney and urinary tract. The primary role of the kidney is to filter blood through the nephrons. These anomalies can result in a reduction in the number of nephrons that are formed during kidney development, or decreased congenital nephron endowment, which is linked to hypertension and chronic kidney disease. It is unknown how exposure to maternal diabetes in utero results in abnormal kidney development and the long-term health consequences of this exposure remain ill-defined. In this study, we profiled gene expression in the developing mouse kidney from C57BL/6J control and maternal diabetes exposed (DM_Exp) mice at single cell resolution. Consistent with previous studies, clusters with distinct transcriptional signatures clearly identify major compartments and cell types of the developing kidney.

2024-11-01 | GSE162298 | GEO

Post-transplant diabetes mellitus after kidney transplantation

Project description:Diabetes mellitus (DM) after transplantation remains a crucial clinical problem in kidney transplantation. To obtain insights into molecular mechanisms underlying the development of post-transplant diabetes mellitus (PTDM) and its early impact on glomerular structures, here we comparatively analyze the proteome of histologically normal appearing glomeruli from patients with PTDM from normoglycemic (NG) transplant recipients, and from recipients with pre-existing type 2 DM (PTDM)

2023-10-24 | PXD042188 | Pride

miRNA expression alterations in liraglutide treated rats arota

Project description:liraglutide may distrub miRNA expression in diabetic rats arota

2019-02-11 | GSE102198 | GEO

The effect of GLP-1 receptor agonist liraglutide on the rat neurointermediate lobe phosphoproteome

Project description:Obesity and its co-morbidities, such as diabetes and hypertension, can significantly reduce a person’s quality of life and place huge pressure on healthcare resources. When we eat a meal our gut and brain release hormones to control the amount of food and fluid we ingest to prevent overeating. One of these hormones is called glucagon-like peptide 1 (GLP-1) and is released from intestinal cells in response to food intake, but also produced and released in the brain. Drug analogues of GLP-1 are already in use in the clinic to treat both diabetes and obesity. The aim of this work was to obtain fundamental knowledge about a GLP-1 receptor population in nerve terminals of the posterior pituitary gland. We have investigated the pharmacological actions of GLP-1 using a selective receptor agonist called liraglutide, a drug that is approved for diabetes and obesity treatment in humans. Our work has focussed on the phosphoproteome of the neurointermediate lobe (posterior pituitary + intermediate lobe) of the rat pituitary gland 30 minutes after intraperitoneal injection of liraglutide (100 µg/kg) compared to vehicle controls (n = 6 animals per group). New understanding of this GLP-1 receptor population is essential for our knowledge of current treatments of diabetes and obesity that use stable peptide analogues in humans.

2023-03-02 | PXD037495 | Pride

Attenuated kidney oxidative metabolism in young adults with type 1 diabetes

Project description:In type 1 diabetes (T1D), impaired insulin sensitivity may contribute to the development of diabetic kidney disease (DKD) through alterations in kidney oxidative metabolism. Young adults with T1D and healthy controls underwent single-cell RNA sequencing, and spatial metabolomics to assess this relationship.

2024-11-11 | GSE279086 | GEO

Gene expression alternations in liraglutide treated rats cardiac muscle

Project description:Diabetic rats changes gene exprssion in liraglutide treated rats cardiac muscle

2018-03-28 | GSE102194 | GEO